253 related articles for article (PubMed ID: 19617343)
1. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of metastases outside the liver and abdominal lymph nodes on
Wedin M; Janson ET; Wallin G; Sundin A; Daskalakis K
J Neuroendocrinol; 2024 May; 36(5):e13391. PubMed ID: 38590270
[TBL] [Abstract][Full Text] [Related]
3. Impact of 68Ga-DOTATOC PET/CT in comparison to 111In-Octreotide SPECT/CT in management of neuro-endocrine tumors: A case report.
Tolomeo A; Lopopolo G; Dimiccoli V; Perioli L; Modoni S; Scilimati A
Medicine (Baltimore); 2020 Feb; 99(7):e19162. PubMed ID: 32049844
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the relative diagnostic performance of
Deng J; Yang J; Wang Y; Liu G; Chen Y
Front Oncol; 2024; 14():1364311. PubMed ID: 38585006
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular magnetic resonance imaging and clinical performance of somatostatin receptor positron emission tomography in cardiac sarcoidosis.
Pizarro C; Kluenker F; Dabir D; Thomas D; Gaertner FC; Essler M; Grohé C; Nickenig G; Skowasch D
ESC Heart Fail; 2018 Apr; 5(2):249-261. PubMed ID: 29231290
[TBL] [Abstract][Full Text] [Related]
6. Al
Diao W; Ye Z; Kou Y; Cheng Z
Hell J Nucl Med; 2024; 27(1):68-70. PubMed ID: 38629821
[TBL] [Abstract][Full Text] [Related]
7. Preoperative assessment of lymph nodal metastases with [
Mapelli P; Bezzi C; Muffatti F; Ghezzo S; Canevari C; Magnani P; Schiavo Lena M; Battistella A; Scifo P; Andreasi V; Partelli S; Chiti A; Falconi M; Picchio M
Eur J Nucl Med Mol Imaging; 2024 May; ():. PubMed ID: 38696129
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin Receptor Imaging with [
Dubash S; Barwick TD; Kozlowski K; Rockall AG; Khan S; Khan S; Yusuf S; Lamarca A; Valle JW; Hubner RA; McNamara MG; Frilling A; Tan T; Wernig F; Todd J; Meeran K; Pratap B; Azeem S; Huiban M; Keat N; Lozano-Kuehne JP; Aboagye EO; Sharma R
J Nucl Med; 2024 Feb; 65(3):416-22. PubMed ID: 38331457
[TBL] [Abstract][Full Text] [Related]
9. (68)Ga-DOTATOC PET and gene expression profile in patients with neuroendocrine carcinomas: strong correlation between PET tracer uptake and gene expression of somatostatin receptor subtype 2.
Olsen IH; Langer SW; Federspiel BH; Oxbøl J; Loft A; Berthelsen AK; Mortensen J; Oturai P; Knigge U; Kjær A
Am J Nucl Med Mol Imaging; 2016; 6(1):59-72. PubMed ID: 27069766
[TBL] [Abstract][Full Text] [Related]
10. PET/CT imaging of neuroendocrine tumors with (68)Gallium-labeled somatostatin analogues: An overview and single institutional experience from India.
Sharma P; Singh H; Bal C; Kumar R
Indian J Nucl Med; 2014 Jan; 29(1):2-12. PubMed ID: 24591775
[TBL] [Abstract][Full Text] [Related]
11. The Additional Value of Somatostatin Receptor Positron Emission Computed Tomography ([
de Bresser CJM; Petri BJ; Braat AJAT; de Keizer B; van Treijen MJC; Dankbaar JW; Pameijer FA; Kok MGJ; de Ridder M; van Nesselrooij BPM; de Bree R; de Borst GJ; Rijken JA
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473347
[TBL] [Abstract][Full Text] [Related]
12. PET and PET/CT with 68gallium-labeled somatostatin analogues in Non GEP-NETs Tumors.
Sollini M; Erba PA; Fraternali A; Casali M; Di Paolo ML; Froio A; Frasoldati A; Versari A
ScientificWorldJournal; 2014; 2014():194123. PubMed ID: 24693229
[TBL] [Abstract][Full Text] [Related]
13. Impairment of lymphocyte function following yttrium-90 DOTATOC therapy.
Barsegian V; Hueben C; Mueller SP; Poeppel TD; Horn PA; Bockisch A; Lindemann M
Cancer Immunol Immunother; 2015 Jun; 64(6):755-64. PubMed ID: 25822768
[TBL] [Abstract][Full Text] [Related]
14. False-Negative Neuroendocrine Tumor Identified With 68Ga-DOTATOC PET/CT: A Case of Well-Differentiated Somatostatinoma.
Moreau A; Chaouat C; Walter T; Dupré A; Kryza D
Clin Nucl Med; 2024 May; ():. PubMed ID: 38689443
[TBL] [Abstract][Full Text] [Related]
15. Global challenges in access to diagnostics and treatment for neuroendocrine tumor (NET) patients.
Dureja S; McDonnell M; Van Genechten D; Bouvier C; Kolarova T; O'Toole D; Singh H; Chen J; Howe J; Singh S; Rodien-Louw C; Leyden S; Gellerman E; Herman J; Pavel M;
J Neuroendocrinol; 2023 Jun; 35(6):e13310. PubMed ID: 37351944
[TBL] [Abstract][Full Text] [Related]
16. Adrenal tumors in patients with neuroendocrine neoplasms.
Falhammar H; Stenman A; Juhlin CC; Kistner A
Endocrine; 2024 Apr; ():. PubMed ID: 38581593
[TBL] [Abstract][Full Text] [Related]
17. [Imaging of neuroendocrine tumors of the gastrointestinal tract : Value of (hybrid) imaging diagnostics in radiology].
Ebner R; Rübenthaler J; Ricke J; Sheikh GT; Unterrainer LM; Auernhammer CJ; Spitzweg C; Brendel M; Schmid-Tannwald C; Cyran CC
Radiologie (Heidelb); 2024 May; ():. PubMed ID: 38713221
[TBL] [Abstract][Full Text] [Related]
18. Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine?
Ouvrard E; Kaseb A; Poterszman N; Porot C; Somme F; Imperiale A
Front Med (Lausanne); 2023; 10():1320574. PubMed ID: 38288299
[TBL] [Abstract][Full Text] [Related]
19. Optimal follow-up with somatostatin receptor PET/CT imaging in patients with small intestinal neuroendocrine tumours.
Ohlsson H; Spaak E; Gålne A; Sundlöv A; Almquist M
J Neuroendocrinol; 2024 Apr; ():e13396. PubMed ID: 38679928
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
